Erk1, Erk2 (Mitogen-activated protein kinase 13, MAP kinase 12) (pThr202, pThr204) antibody
| Antigen | Erk1, Erk2 (Mitogen-activated protein kinase 13, MAP kinase 12) |
| Binding Site |
Alternatives pThr202, pThr204 |
| Clonality | Polyclonal |
| Host |
Alternatives Sheep |
| Application |
Alternatives Immunohistochemistry (IHC), Western Blotting (WB) |
![]() |
5 references available |
| Catalog no. | ABIN350734 |
| Quantity | 100 µl (Variants) |
| Price | 454.67 $ Plus shipping costs $45.00 |
| Shipping to |
|
| Availability | Will be delivered in 7 to 8 Business Days |
Additional Information
| UniProt | P27361 |
| Immunogen | A synthetic peptide from the phospho T202 & Y204 of human Erk1, Erk2 (Mitogen-activated protein kinase 1 & 3, MAP kinase 1 & 2) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen is homologous in many species including rat, mouse, zebra fish, xenopus and chicken. |
| Format | Lyophilized |
| Description | FUNCTION: Involved in both the initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors such as ELK-1. Phosphorylates EIF4EBP1; required for initiation of translation. Phosphorylates microtubule-associated protein 2 (MAP2). Phosphorylates SPZ1. Phosphorylates heat shock factor protein 4 (HSF4). CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein. COFACTOR: Magnesium. ENZYME REGULATION: Activated by tyrosine phosphorylation in response to insulin and NGF. SUBUNIT: Interacts with MORG1. Binds to HIV-1 Nef. This interaction inhibits its kinase activity. Interacts with HSF4 and NISCH. Also known as: Mitogen-activated protein kinase 3, Extracellular signal-regulated kinase 1, Insulin-stimulated MAP2 kinase, MAP kinase 1, MAPK 1, p44-ERK1, ERT2, p44-MAPK, Microtubule-associated protein 2 kinase, Mitogen-activated protein kinase 1, Extracellular signal-regulated kinase 2, ERK-2, Mitogen-activated protein kinase 2, MAP kinase 2, MAPK 2, p42-MAPK, ERT1, MAPK1, PRKM1, PRKM2, MAPK3, PRKM3. |
| Specificity | Appears to be specific for Erk1 and Erk2. |
Application Details
| Application Notes | IHC, WB. A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. This antibody may also recognise the unphosphorylated form. Not yet tested in other applications. |
| Purity | whole serum |
| Storage | Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles. |
| Restrictions | For Research Use only |
Publications
|
Charest, Mordret, Harder et al.: "Molecular cloning, expression, and characterization of the human mitogen-activated protein kinase p44erk1." in: Molecular and cellular biology, Vol. 13, Issue 8, pp. 4679-90, 1993 (PubMed).
Zhang, Wolf-Yadlin, Ross et al.: "Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules." in: Molecular & cellular proteomics : MCP, Vol. 4, Issue 9, pp. 1240-50, 2005 (PubMed). Olsen, Blagoev, Gnad et al.: "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." in: Cell, Vol. 127, Issue 3, pp. 635-48, 2006 (PubMed). Wissing, Jänsch, Nimtz et al.: "Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry." in: Molecular & cellular proteomics : MCP, Vol. 6, Issue 3, pp. 537-47, 2007 (PubMed). Rikova, Guo, Zeng et al.: "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer." in: Cell, Vol. 131, Issue 6, pp. 1190-203, 2007 (PubMed). |
|
Alternatives
Alternatives for antigen "Erk1, Erk2 (Mitogen-activated protein kinase 13, MAP kinase 12)", type "Antibodies"
| Hosts | Rabbit (3), Sheep (1) |
| Applications | Immunohistochemistry (IHC) (4), Western Blotting (WB) (4) |
| Epitopes | pThr202, pThr204 (3), Internal Region (1) |




Alternatives